CEO Conrad Wai sells 220,426 shares of CLOV at $3.99; 10b5-1 plan execution; stock up 58.3% in 30 days.
Conrad Wai, CEO of Counterpart Health, sold 220,426 shares of Clover Health at $3.99 on 2026-05-28 under a pre-arranged 10b5-1 trading plan adopted on 2025-03-03, reducing his holdings from 1.61M shares to 1.39M shares. The sale occurs against a backdrop of sharp recent price appreciation: the stock has risen 58.3% over the prior 30 days and 100.0% over the prior 90 days, trading at $4.18 currently versus a 52-week high of $3.92. At the same ticker, Wai's prior two sales (2025-07-23 and 2025-07-22) were followed by negative 30-day and 90-day returns, though this transaction is scheduled under the 10b5-1 plan rather than discretionary. The company reported $749.2M in latest quarterly revenue (+40.3% annual growth) and $27.3M in net income, though it posted negative full-year net income over its most recent fiscal year, presenting a mixed financial picture.